Cosibelimab - CAS 2216751-26-5

Cosibelimab (CK-301; TG-1501) is a fully human, high-affinity monoclonal antibody that inhibits PD-L1 by preventing its interaction with PD-1. Featuring a functional Fc domain, this compound effectively induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), targeting and eliminating PD-L1+ cell lines, including lymphoma cells [1].

PD-1/PD-L1

Immunology/Inflammation, Apoptosis, Cell Cycle/Checkpoint

2216720

-20°C

Ice Packs

Inhibitory Antibodies